Maria Sundvall
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Immune checkpoint therapies (ICT) have provided remarkable improvements in the treatment and clinical response of solid tumors. However, almost half of metastatic melanoma patients develop resistance to ICT because of ‘cold tumor’ formation, characterized by a lack of CD8+ T cell infiltration. Currently, there are no effective tools to predict the development of cold tumors and subsequent lack of response to ICT. Therefore, there is a persisting clinical need for accurate prognostic models and discovery of functional drivers of cold tumors. In this study, we sought to develop a prognostic model based on features that drive poor immunogenicity in metastatic melanomas. Our model development strategy identified immune triggers that predict RECIST outcomes in both cold and hot tumors. We developed a systems immunology approach that identifies immune signatures from whole-transcriptome data across multiple ICT-treated metastatic melanoma cohorts, focusing on biomarkers related to antigen processing and CD8+ T cell priming (APP). These signatures were integrated into a model to identify the most Predictive Ranking-based Immunogenic Markers for Efficacy (PRIME) in anti-PD1 prognostication for melanoma. These immune signatures also guided functional biomarker discovery through unsupervised clustering of gene expression, clinical, and functional data. Biomarkers were further filtered by spatial transcriptomics and single-cell RNA sequencing to highlight those linked with dendritic cells (DCs) and CD8+ T cell priming interactions. These biomarkers were functionally validated using siRNA knockdown in human monocyte-DCs (moDCs) and antigen presentation studies. Our bioinformatic analysis identified 3,359 and 2,902 genes positively and negatively associated with survival in ICT-treated patients. From these, 667 genes from the positive group and 129 genes from the negative group showed a significant correlation with APP. The PRIME prognostic model, integrating components of these signatures, outperformed the existing models (IMPRES and TIDE) in predicting RECIST responses to anti-PD1 ICT in pre-treatment samples of cutaneous metastatic melanoma patients. The spatial transcriptomics of skin metastases and single-cell profiling identified enriched targets without previously known roles in DC's immunogenic functions, two of which were selected for functional validation. We observed that these biomarkers may play a role in sustaining APP through the regulation of peptide processing and costimulatory/coinhibitory machinery in human moDCs. Our findings present PRIME as a novel anti-PD1 prognostication model focused on the immunogenic characteristics of metastatic melanoma. The model’s efficacy likely stems from the functional properties of its subcomponents, highlighting new potential targets for rational combination therapies aimed at enhancing tumor immunogenicity by optimizing CD8+ T cell priming and improving anti-PD1 response outcomes. Citation Format: Saara A Koskela, Otto Pulkkinen, Arfa Mehmood, Eva-Maria Birkman, Tero Aittokallio, Maria Sundvall, Carlos R Figueiredo. PRIME: An integrative systems immunology approach to predict anti-PD1 responses and discover new targets for melanoma immunotherapy [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr A109.
Year:
2025
Year:
2025
Lethal prostate cancer (PCa) is a genetically heterogeneous disease characterized by evolving androgen receptor (AR) signaling, eventually culminating in castration resistance. The tumor suppressor gene BRCA1 has multiple functions that include secondary processes cooperating with its main function as a caretaker of genomic integrity. BRCA1 is often mutated in breast and ovarian cancer, but BRCA1 mutations are also associated with PCa, although they are less frequently observed. Most PCa patients do not, however, carry BRCA1 mutations, and interestingly, it has been shown that BRCA1 expression is enriched in castration‐resistant PCa. In this study we elucidated the prostate tissue‐specific role of the BRCA1 protein. Although the regulation of DNA damage response genes has been studied in PCa, comprehensive analyses of BRCA1 regulation in the context of androgen signaling are lacking. Our results indicate that BRCA1 is dynamically regulated by AR signaling and that activation of AR via its natural ligand, dihydrotestosterone, represses BRCA1 expression. Our analyses both in vitro and of patient samples and mouse xenografts showed that BRCA1 expression was induced and sustained after androgen deprivation. Moreover, we observed that oxidative stress–related pathways were regulated by BRCA1 in PCa cells and that androgen deprivation therapy–induced activation of BRCA1 supported the function of NRF2, the master regulator of antioxidant defense, and a known interactor of BRCA1. Impaired NRF2 activity, in the absence of BRCA1, decreased growth in a 3D environment. Our findings shed light on the functional role of BRCA1 protein in PCa and suggest that BRCA1 is regulated by the evolving AR signaling state during PCa progression. Thus, AR‐mediated suppression of BRCA1 accumulates oncogenic alterations in the early phases of PCa tumor progression and safeguards from excessive reactive oxygen species (ROS) when upregulated during androgen deprivation therapy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Year:
2025
Year:
2025
Despite the success of anti-PD1 immunotherapy in melanoma, identifying biomarkers for response prediction and rational treatment combinations remains a major challenge. Effective dendritic cell (DC):CD8+ T cell crosstalk in the tumor microenvironment enhances anti-PD1 responses; however, no predictive signatures reflect this interaction. To address this, we developed a systems immunology approach based on DC:CD8+ T cell crosstalk reference biomarkers CD74 and CD8A, leading to the discovery of a 15-gene immune signature called PRIME, incorporated into a logistic regression framework for anti-PD1 response prediction in melanoma. PRIME outperforms previous signatures, especially in tumors with high CD8+ T cells, reflecting a functional immune response. Integrating clinical, molecular, spatial, and single-cell profiling identified SLAMF7 and TYMP as new functional biomarker candidates in DCs. Mechanistic studies revealed that these biomarkers regulate antigen processing and presentation in DCs. Our study demonstrates a new strategy for predicting anti-PD1 responses in melanoma, revealing biomarkers with functional roles that may inform future therapeutic development.
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2021
Year:
2021
Collaborators (17)
Tuomas Mirtti
University of Helsinki
Otto Ettala
Helsinki University Hospital
Lea Sistonen
Åbo Akademi University
Anna K Kirjavainen
Senior researcher
University of Turku
Marja Jaattela
Professor in Cell Death and Metabolism
University of Copenhagen
Panu Jaakkola
Research director
University of Helsinki
Carlos Rogerio de Figueiredo
Associate Professor / ImmunoCAP Research Fellow
University of Turku
Satu Mustjoki
University of Helsinki
Kalle E. Mattila
Helsinki University Hospital
Roosa Kallionpää
University of Turku
Jukka Kemppainen
Professor in Clinical Physiology and Nuclear Medicine
University of Turku
Pieta K. Mattila
Group leader
University of Turku
Heikki Minn
Professor emeritus
Helsinki University Hospital
Ilkka Paatero
-
Teemu Daniel Laajala
Docent (Associate / Adjunct Professor)
University of Helsinki
Pekka Taimen
-
Klaus Elenius
professor of medical biochemistry
University of Turku
Make your next move.
Prepare your application
Review drafts before you send them.